TY - JOUR
T1 - Novel role of the serine protease inhibitor elafin in gluten-related disorders
AU - Galipeau, Heather J.
AU - Wiepjes, Michelle
AU - Motta, Jean Paul
AU - Schulz, Jessica D.
AU - Jury, Jennifer
AU - Natividad, Jane M.
AU - Pinto-Sanchez, Ines
AU - Sinclair, Daniel
AU - Rousset, Perrine
AU - Martin-Rosique, Rebeca
AU - Bermudez-Humaran, Luis
AU - Leroux, Jean Christophe
AU - Murray, Joseph A.
AU - Smecuol, Edgardo
AU - Bai, Julio C.
AU - Vergnolle, Nathalie
AU - Langella, Philippe
AU - Verdu, Elena F.
PY - 2014/5
Y1 - 2014/5
N2 - Objectives: Elafin, an endogenous serine protease inhibitor, modulates colonic inflammation. We investigated the role of elafin in celiac disease (CD) using human small intestinal tissues and in vitro assays of gliadin deamidation. We also investigated the potential beneficial effects of elafin in a mouse model of gluten sensitivity. Methods: Epithelial elafin expression in the small intestine of patients with active CD, treated CD, and controls without CD was determined by immunofluorescence. Interaction of elafin with human tissue transglutaminase-2 (TG-2) was investigated in vitro. The 33-mer peptide, a highly immunogenic gliadin peptide, was incubated with TG-2 and elafin at different concentrations. The degree of deamidation of the 33-mer peptide was analyzed by liquid chromatography-mass spectrometry. Elafin was delivered to the intestine of gluten-sensitive mice using a recombinant Lactococcus lactis vector. Small intestinal barrier function, inflammation, proteolytic activity, and zonula occludens-1 (ZO-1) expression were assessed. Results: Elafin expression in the small intestinal epithelium was lower in patients with active CD compared with control patients. In vitro, elafin significantly slowed the kinetics of the deamidation of the 33-mer peptide to its more immunogenic form. Treatment of gluten-sensitive mice with elafin delivered by the L. lactis vector normalized inflammation, improved permeability, and maintained ZO-1 expression. Conclusions: The decreased elafin expression in the small intestine of patients with active CD, the reduction of 33-mer peptide deamidation by elafin, coupled to the barrier enhancing and anti-inflammatory effects observed in gluten-sensitive mice, suggest that this molecule may have pathophysiological and therapeutic importance in gluten-related disorders.
AB - Objectives: Elafin, an endogenous serine protease inhibitor, modulates colonic inflammation. We investigated the role of elafin in celiac disease (CD) using human small intestinal tissues and in vitro assays of gliadin deamidation. We also investigated the potential beneficial effects of elafin in a mouse model of gluten sensitivity. Methods: Epithelial elafin expression in the small intestine of patients with active CD, treated CD, and controls without CD was determined by immunofluorescence. Interaction of elafin with human tissue transglutaminase-2 (TG-2) was investigated in vitro. The 33-mer peptide, a highly immunogenic gliadin peptide, was incubated with TG-2 and elafin at different concentrations. The degree of deamidation of the 33-mer peptide was analyzed by liquid chromatography-mass spectrometry. Elafin was delivered to the intestine of gluten-sensitive mice using a recombinant Lactococcus lactis vector. Small intestinal barrier function, inflammation, proteolytic activity, and zonula occludens-1 (ZO-1) expression were assessed. Results: Elafin expression in the small intestinal epithelium was lower in patients with active CD compared with control patients. In vitro, elafin significantly slowed the kinetics of the deamidation of the 33-mer peptide to its more immunogenic form. Treatment of gluten-sensitive mice with elafin delivered by the L. lactis vector normalized inflammation, improved permeability, and maintained ZO-1 expression. Conclusions: The decreased elafin expression in the small intestine of patients with active CD, the reduction of 33-mer peptide deamidation by elafin, coupled to the barrier enhancing and anti-inflammatory effects observed in gluten-sensitive mice, suggest that this molecule may have pathophysiological and therapeutic importance in gluten-related disorders.
UR - http://www.scopus.com/inward/record.url?scp=84899919523&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899919523&partnerID=8YFLogxK
U2 - 10.1038/ajg.2014.48
DO - 10.1038/ajg.2014.48
M3 - Article
C2 - 24710505
AN - SCOPUS:84899919523
SN - 0002-9270
VL - 109
SP - 748
EP - 756
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 5
ER -